| Attribute |
Value |
| 52 Week Change |
-0.6413044 |
| Address1 |
Building C |
| Address2 |
10th Floor 10 Habarzel Street |
| All Time High |
736.0 |
| All Time Low |
1.35 |
| Ask |
1.92 |
| Ask Size |
1 |
| Average Analyst Rating |
2.0 - Buy |
| Average Daily Volume10 Day |
507,900 |
| Average Daily Volume3 Month |
120,591 |
| Average Volume |
120,591 |
| Average Volume10Days |
507,900 |
| Beta |
0.635 |
| Bid |
1.97 |
| Bid Size |
1 |
| Book Value |
1.485 |
| City |
Tel Aviv-Yafo |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Israel |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.65 |
| Current Ratio |
10.309 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
1.8 |
| Day Low |
1.57 |
| Display Name |
Chemomab Therapeutics |
| Earnings Timestamp End |
1,756,119,600 |
| Earnings Timestamp Start |
1,755,601,200 |
| Ebitda |
-7,855,750 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.489 |
| Enterprise Value |
3,837,623 |
| Eps Current Year |
-0.02 |
| Eps Forward |
-0.03 |
| Eps Trailing Twelve Months |
-1.02 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.76266 |
| Fifty Day Average Change |
-0.11266005 |
| Fifty Day Average Change Percent |
-0.06391479 |
| Fifty Two Week Change Percent |
-64.13044 |
| Fifty Two Week High |
4.84 |
| Fifty Two Week High Change |
-3.19 |
| Fifty Two Week High Change Percent |
-0.6590909 |
| Fifty Two Week Low |
1.35 |
| Fifty Two Week Low Change |
0.29999995 |
| Fifty Two Week Low Change Percent |
0.22222218 |
| Fifty Two Week Range |
1.35 - 4.84 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,549,981,800,000 |
| Float Shares |
6,395,736 |
| Forward Eps |
-0.03 |
| Forward P E |
-55.0 |
| Full Exchange Name |
NasdaqCM |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.11088 |
| Held Percent Institutions |
0.04759 |
| Implied Shares Outstanding |
7,327,660 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,756,166,400 |
| Last Split Factor |
1:4 |
| Long Business Summary |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel. |
| Long Name |
Chemomab Therapeutics Ltd. |
| Market |
us_market |
| Market Cap |
12,090,639 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_323539890 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-7,445,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
11,650,979 |
| Number Of Analyst Opinions |
1 |
| Open |
1.71 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
972 77 331 0156 |
| Pre Market Change |
0.08000004 |
| Pre Market Change Percent |
4.8484874 |
| Pre Market Price |
1.73 |
| Pre Market Time |
1,784,030,105 |
| Previous Close |
1.74 |
| Price Eps Current Year |
-82.5 |
| Price Hint |
4 |
| Price To Book |
1.111111 |
| Profit Margins |
0.0 |
| Quick Ratio |
10.309 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.0 |
| Region |
US |
| Regular Market Change |
-0.09 |
| Regular Market Change Percent |
-5.17242 |
| Regular Market Day High |
1.8 |
| Regular Market Day Low |
1.57 |
| Regular Market Day Range |
1.57 - 1.8 |
| Regular Market Open |
1.71 |
| Regular Market Previous Close |
1.74 |
| Regular Market Price |
1.65 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
210,062 |
| Return On Assets |
-0.40251 |
| Return On Equity |
-0.70609003 |
| Sand P52 Week Change |
0.20365608 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
7,327,660 |
| Shares Percent Shares Out |
0.0199 |
| Shares Short |
143,144 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
38,648 |
| Short Name |
Chemomab Therapeutics Ltd. |
| Short Percent Of Float |
0.020399999 |
| Short Ratio |
3.3 |
| Source Interval |
15 |
| Symbol |
CMMB |
| Target High Price |
5.0 |
| Target Low Price |
5.0 |
| Target Mean Price |
5.0 |
| Target Median Price |
5.0 |
| Total Cash |
8,043,000 |
| Total Cash Per Share |
1.117 |
| Total Debt |
0 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-1.02 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
2.039275 |
| Two Hundred Day Average Change |
-0.38927495 |
| Two Hundred Day Average Change Percent |
-0.1908889 |
| Type Disp |
Equity |
| Volume |
210,062 |
| Website |
https://www.chemomab.com |
| Zip |
6,158,101 |